Johnson, Melissa D.

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 778

Human dectin-1 deficiency and mucocutaneous fungal infections

Ferwerda, B., Ferwerda, G., Plantinga, T. S., Willment, J. A., van Spriel, A. B., Venselaar, H., Elbers, C. C., Johnson, M. D., Cambi, A., Huysamen, C., et al. (2009) · New England Journal of Medicine

Immunodeficiency and Autoimmune DisordersAntifungal resistance and susceptibility

Cited by 752

Combination antifungal therapy

Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 541

CX3CR1-dependent renal macrophage survival promotes Candida control and host survival

Lionakis, M. S., Swamydas, M., Fischer, B. G., Plantinga, T. S., Johnson, M. D., Jaeger, M., Green, N. M., Masedunskas, A., Weigert, R., Mikelis, C., et al. (2013) · Journal of Clinical Investigation

Antifungal resistance and susceptibilityChemokine receptors and signaling

Cited by 230

Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans

Smeekens, S. P., Ng, A., Kumar, V., Johnson, M. D., Plantinga, T. S., van Diemen, C., Arts, P., Verwiel, E. T. P., Gresnigt, M. S., Fransen, K., et al. (2013) · Nature Communications

Antifungal resistance and susceptibilityinterferon and immune responses

Cited by 213

Collaborative Drug Therapy Management and Comprehensive Medication Management―2015

American College of Clinical Pharmacy, McBane, S. E., Dopp, A. L., Abe, A., Benavides, S., Chester, E. A., Dixon, D. L., Dunn, M., Johnson, M. D., Nigro, S. J., et al. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Pharmacy and Medical PracticesPharmaceutical Practices and Patient Outcomes

Cited by 184

Caspofungin: first approved agent in a new class of antifungals

Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 85

Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options

Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 62

Antifungals in Clinical Use and the Pipeline

Johnson, M. D. (2021) · Infectious Disease Clinics of North America

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 35